Literature DB >> 3594409

Inflammatory breast cancer. Determination of prognostic factors by univariate and multivariate analysis.

B Chevallier, B Asselain, A Kunlin, C Veyret, P Bastit, Y Graic.   

Abstract

Between January 1977 and June 1983, 64 consecutive patients were treated for unilateral inflammatory nonmetastatic breast cancer. Our protocol included three or four courses of induction chemotherapy, then locoregional irradiation therapy with Co-60, followed by maintenance chemotherapy only if induction chemotherapy had proven effective. Eight patients with a residual tumor after radiotherapy underwent a modified radical mastectomy. Actuarial 3-year overall survival for the whole group was 38%, and the median disease-free survival time was 19 months. The effect of 17 factors on overall survival or disease-free survival was analyzed. With univariate analysis, eight factors were found to affect overall survival or disease-free survival: extent of initial erythema, size of initial edema, lymph node involvement, erythema present at the end of initial chemotherapy, erythema present at the end of radiotherapy, tumor size at the end of induction chemotherapy, residual breast tumor at the end of maintenance chemotherapy, and performance of a radical mastectomy. Age at diagnosis, menopausal status, type of chemotherapy, and date of appearance of inflammatory signs did not influence prognosis. Multivariate analysis using the Cox proportional hazard model isolated three bad prognosis factors: erythema involving the whole breast at initial diagnosis, erythema present at the end of initial chemotherapy, and lymph node involvement.

Entities:  

Mesh:

Year:  1987        PMID: 3594409     DOI: 10.1002/1097-0142(19870815)60:4<897::aid-cncr2820600430>3.0.co;2-s

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  12 in total

1.  Inflammatory carcinoma of the breast: results of a combined-modality approach--M.D. Anderson Cancer Center experience.

Authors:  E H Koh; A U Buzdar; F C Ames; S E Singletary; M D McNeese; D Frye; F A Holmes; G Fraschini; V Hug; R L Theriault
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  Semiquantitative analysis of maximum standardized uptake values of regional lymph nodes in inflammatory breast cancer: is there a reliable threshold for differentiating benign from malignant?

Authors:  Selin Carkaci; Beatriz E Adrada; Eric Rohren; Wei Wei; Mohammad A Quraishi; Osama Mawlawi; Thomas A Buchholz; Wei Yang
Journal:  Acad Radiol       Date:  2012-02-01       Impact factor: 3.173

3.  Inflammatory Breast Cancer Outcomes in a Contemporary Series.

Authors:  Elizabeth Pan; Lily Tung; Omar Ragab; Elise Morocco; Julie Wecsler; Richard Sposto; Akshara Raghavendra; Eugene Chung; Julie E Lang
Journal:  Anticancer Res       Date:  2017-09       Impact factor: 2.480

4.  Therapy for inflammatory breast cancer: impact of doxorubicin-based therapy.

Authors:  R L Bauer; E Busch; E Levine; S B Edge
Journal:  Ann Surg Oncol       Date:  1995-07       Impact factor: 5.344

Review 5.  The possible role of stromal cell stimulation in worsening the prognosis of a subset of patients with breast cancer.

Authors:  T H Stewart; S C Tsai
Journal:  Clin Exp Metastasis       Date:  1993-07       Impact factor: 5.150

6.  Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong E-cadherin expression.

Authors:  C G Colpaert; P B Vermeulen; I Benoy; A Soubry; F van Roy; P van Beest; G Goovaerts; L Y Dirix; P van Dam; S B Fox; A L Harris; E A van Marck
Journal:  Br J Cancer       Date:  2003-03-10       Impact factor: 7.640

7.  First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial).

Authors:  P Viens; T Palangié; M Janvier; M Fabbro; H Roché; T Delozier; J P Labat; C Linassier; B Audhuy; F Feuilhade; B Costa; R Delva; H Cure; F Rousseau; A Guillot; M Mousseau; J M Ferrero; V J Bardou; J Jacquemier; P Pouillart
Journal:  Br J Cancer       Date:  1999-10       Impact factor: 7.640

8.  The Centre H. Becquerel studies in inflammatory non metastatic breast cancer. Combined modality approach in 178 patients.

Authors:  B Chevallier; P Bastit; Y Graic; J F Menard; J P Dauce; J P Julien; B Clavier; A Kunlin; J D'Anjou
Journal:  Br J Cancer       Date:  1993-03       Impact factor: 7.640

Review 9.  Inflammatory breast cancer: clinical progress and the main problems that must be addressed.

Authors:  Sharon H Giordano; Gabriel N Hortobagyi
Journal:  Breast Cancer Res       Date:  2003-08-26       Impact factor: 6.466

Review 10.  Update on inflammatory breast cancer.

Authors:  Florence Lerebours; Ivan Bieche; Rosette Lidereau
Journal:  Breast Cancer Res       Date:  2005-01-20       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.